Myelodysplastic Syndrome — Trials

Myelodysplastic Syndrome — Trials · CancerIndex

Clinical trials

Registered studies

1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 336
Recruiting: 196
Ph III recruiting: 9
Growth YoY: +2.1%
Industry share: 20%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 33.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (307)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03795779	CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies	unknown	Early Phase 1	20	iCell Gene TherapeuticsINDUSTRY	1	May 19, 2021	clinicaltrials
NCT04156256	CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies	unknown	Early Phase 1	20	iCell Gene TherapeuticsINDUSTRY	1	Nov 12, 2019	clinicaltrials